Cargando…
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temp...
Autores principales: | Cavedo, Enrica, Grothe, Michel J., Colliot, Olivier, Lista, Simone, Chupin, Marie, Dormont, Didier, Houot, Marion, Lehéricy, Stephane, Teipel, Stefan, Dubois, Bruno, Hampel, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601919/ https://www.ncbi.nlm.nih.gov/pubmed/28916821 http://dx.doi.org/10.1038/s41598-017-09780-3 |
Ejemplares similares
-
Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors
por: Teipel, Stefan J., et al.
Publicado: (2018) -
Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease
por: Teipel, Stefan J., et al.
Publicado: (2020) -
Differential response to donepezil in MRI subtypes of mild cognitive impairment
por: Diaz-Galvan, Patricia, et al.
Publicado: (2023) -
Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment
por: Diaz‑Galvan, Patricia, et al.
Publicado: (2023) -
In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s disease
por: Ray, Nicola J, et al.
Publicado: (2018)